Loading with 600 mg clopidogrel in patients with coronary artery disease with and without chronic clopidogrel therapy

• Published in: Circulation (New York, N.Y.) N.Y.), 2004-10, Vol.110 (14), p.1916-1919
• Main Authors: KASTRATI, Adnan, VON BECKERATH, Nicolas, JOOST, Alexander, POGATSA-MURRAY, Gisela, GORCHAKOVA, Olga, SCHÖMIG, Albert
• Format: Article
• Language: English
• Subjects: Aged; Aspirin - therapeutic use; Biological and medical sciences; Blood and lymphatic vessels; Blood Platelets - chemistry; Blood Platelets - drug effects; Blood. Blood coagulation. Reticuloendothelial system; C-Reactive Protein - analysis; Cardiology. Vascular system; Cohort Studies; Coronary Angiography; Coronary Disease - drug therapy; Coronary heart disease; Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Heart; Humans; Male; Medical sciences; Middle Aged; P-Selectin - blood; Pharmacology. Drug treatments; Platelet Aggregation - drug effects; Platelet Aggregation Inhibitors - administration & dosage; Platelet Aggregation Inhibitors - therapeutic use; Platelet Glycoprotein GPIIb-IIIa Complex - analysis; Prospective Studies; Ticlopidine - administration & dosage; Ticlopidine - analogs & derivatives; Ticlopidine - therapeutic use
• ISSN: 0009-7322; 1524-4539
• DOI: 10.1161/01.CIR.0000137972.74120.12

It is not known whether further suppression of platelet function can be achieved with clopidogrel beyond that provided by currently recommended loading and maintenance doses. We performed a comparative assessment of the antiplatelet effects of a 600-mg loading dose of clopidogrel given to patients with and without chronic clopidogrel therapy. Those eligible for this prospective study were aspirin-treated patients with suspected or documented coronary artery disease admitted to hospital for coronary angiography. Two series of 20 consecutive patients each were assessed in this study. The first series included patients who had never received clopidogrel (first-use group); the second series included patients on chronic therapy with a daily dose of 75 mg clopidogrel for > or =1 month (chronic therapy group). Blood samples were drawn before and 6 hours after oral administration of 600 mg clopidogrel for aggregometry and flow cytometry studies. In the first-use group, loading with 600 mg clopidogrel inhibited ADP 5 micromol/L-induced platelet aggregation from 90+/-9% to 51+/-19% (P